2022
21 Sickle Cell Disease Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Children Undergoing Hematopoietic Cellular Therapy
Schoettler M, Spencer K, Lutterman D, Rumbika S, Haight A, Stenger E, Parikh S, Qayed M, Watkins B, Krishnamurti L, Williams K, Chonat S. 21 Sickle Cell Disease Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Children Undergoing Hematopoietic Cellular Therapy. Transplantation And Cellular Therapy 2022, 28: s20-s21. DOI: 10.1016/s2666-6367(22)00182-8.Peer-Reviewed Original Research
2015
Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation
Stenger E, Krishnamurti L, Galipeau J. Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation. BMC Immunology 2015, 16: 74. PMID: 26674007, PMCID: PMC4681052, DOI: 10.1186/s12865-015-0135-7.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationMesenchymal stromal cellsCell transplantationPost-hematopoietic cell transplantationStromal cellsHematopoietic stem cell engraftmentPre-clinical studiesStem cell engraftmentHost diseaseImmune reconstitutionClinical trialsAnimal modelsCell engraftmentMultipotent progenitor cellsImmune systemHSC engraftmentCellular therapyProgenitor cellsTransplantationEngraftmentTrialsDual effectCellsEarly evidenceGVHD